U.S. Markets closed

Gilead CEO becomes billionaire on Sovaldi prospects, Bloomberg says

Gilead Sciences CEO John Martin has become a billionaire on the prospects of Sovaldi, a new hepatitis C drug that’s attracting scrutiny from payers and activists over its $1K per pill cost, reported Bloomberg. Sovaldi costs $84K for a 12-week course and is expected to produce $4.2B in revenue this year.